¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"level-dependent frequency response"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • anamnestic response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • biologic response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • biological response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • brain stem evoked response audiometry
    ³úÁÙ±âÀ¯¹ß¹ÝÀÀû·Â°Ë»ç
  • concentration-response curve
    ³óµµ¹ÝÀÀ°î¼±
  • conditioned response
    Á¶°Ç¹ÝÀÀ
  • consummatory response
    ¼ºÃë¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • chemotactic response
    È­ÇÐÁÖ¼º¹ÝÀÀ, È­Çнò¸²¹ÝÀÀ
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • evoked response
    À¯¹ß¹ÝÀÀ
  • evoked response audiometry
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀû·Â°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • radio-frequency pulse sequence
    °íÁÖÆÄÆÞ½º¿¬¼â
  • sound frequency spectrum
    À½ÇâÁ֯ļö½ºÆåÆ®·³
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    (¢¡secondary immune response) ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • brainstem evoked response audiometry
    ³úÁÙ±âÀ¯¹ß¹ÝÀÀû·Â°Ë»ç
  • evoked response audiometry
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀû·Â°Ë»ç
  • startle response audiometry
    ³î¶÷¹ÝÀÀû·Â°Ë»ç
  • stimulus response assessment
    ÀڱعÝÀÀÆò°¡
  • biologic response modifier
    »ýü¹ÝÀÀÁ¶Àý¹°Áú, »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦
  • bulbocavernous evoked-response test
    ¸Á¿ïÇØ¸éü±ÙÀ¯µµ¹ÝÀÀ°Ë»ç
  • response bias
    ¹ÝÀÀ¹ÙÀ̾
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • frequency modulation
    Á֯ļöº¯Á¶(ñ²÷îâ¦Ü¨ðà).
  • frequency modulation
    Á֯ļö º¯Á¶
  • frequency modulation imaging
    Á֯ļö º¯Á¶ ¿µ»ó
  • frequency of allele
    ´ë¸³ÀÎÀÚºóµµ
  • frequency of beam
    À½¼Ó (ëåáÖ) ÀÇ Á֯ļö (ñ²÷îâ¦)
  • frequency of occurrence
    ¹ß»ýºóµµ(ËÑË×Ë×̬).
  • frequency of urination
    ¿äÀǺóµµ(èñëòÞºöô).
  • frequency perturbation
    À½Á¶ÀÇ º¯µ¿À²
  • frequency polygon
    µµ¼öÀý¼±µµ.
  • frequency polygon
    µµ¼öÀý¼±µµ
  • frequency range
    Á֯ļö ¹üÀ§
  • frequency selective fat suppression technique
    Á֯ļö ¼±Åà Áö¹æ ¾ïÁ¦(±â)¹ý
  • frequency selectivity
    Á֯ļö ¼±º°·Â
  • high frequency
    °íÁÖÆÄ(¼ö)
  • high frequency jet ventilation =HFJV
    °íºóµµÁ¦Æ®È¯±â.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • high frequency positive pressure ventilation =HFPPV
    °íºóµµ¾ç¾Ðȯ±â.
  • high frequency recombination (Hfr)
    °íºóµµÀçÁ¶ÇÕ
  • high frequency transducing lysate
    °íºóµµÇüÁúµµÀÔ ¿ë±Õ¹°
  • high frequency transduction
    °íºóµµÇüÁúµµÀÔ
  • high frequency ventilation = HFV
    °íºóµµÈ¯±â
  • high spatial frequency algorithm
    °í °ø°£ Á֯ļö ¿¬»ê
  • low frequency
    ÀúÁÖÆÄ
  • low frequency deafness
    ÀúÁ֯ijó, ÀúÁÖÆÄ±Í¸ÔÀ½
  • low frequency therapeutic apparatus
    ÀúÁÖÆÄÄ¡·á±â
  • low frequency therapeutic apparatus
    ÀúÁÖÆÄÄ¡·á±â(î¸ñ²÷îö½èþÐï).
  • low frequency transduction
    Àúºóµµ ÇüÁúµµÀÔ
  • mutant frequency
    (µ¹¿¬)º¯ÀÌüºóµµ(¡­ô÷Þºöô).
  • nystagmus frequency
    ¾ÈÁø(ÀÇ) ºóµµ
  • operating frequency
    ÀÛµ¿ Á֯ļö
  • otoacoustic emission, stimulus frequency
    ÀڱغóµµÀÌÀ½Çâ¹æ»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
SER sebum excretion rate; sensitizer enhancement ratio; sensory evoked response; service; smooth endopla...
SIRS soluble immune response suppressor; Structured Interview of Reported Symptoms; systemic inflammatory...
WR Wassermann reaction; water retention; weakly reactive; weak response; whole response; wiping reactio...
af audio frequency
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
FR Frequency
FDT Frequency Doubling Technology
FM Frequency Modulated
FM Frequency modulation
FTC frequency tuning curve
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • high-frequency oscillation
    °íÁÖÆÄ Áøµ¿
  • low frequency
    ÀúÁÖÆÄ
    Á֯ļö°¡ ³·Àº ÆÄ. Áï, ÀüÀÚ±âÆÄÀÇ Á֯ļö¿¡ ÀÇÇÑ ºÐ·ù·Î¼­, º¸Åë 10 kHz ÀÌÇϸ¦ ¸»ÇÑ´Ù. ¿Àµð¿À
  • low frequency therapeutic apparatus
    ÀúÁÖÆÄ Ä¡·á±â
  • low-frequency wave
    ÀúÁÖÆÄ
  • mutant frequency
    º¯ÀÌü ºóµµ, µ¹¿¬º¯ÀÌü ºóµµ
  • phase frequency swap
    À§»ó Á֯ļö ±³È¯
  • radio-frequency
    °íÁÖÆÄ, ¹æ¼ÛÆÄ
  • radio-frequency coil
    °íÁÖÆÄ ÄÚÀÏ
  • radio-frequency field
    °íÁÖÆÄ ÀÚÀå
  • radio-frequency interference
    °íÁÖÆÄ °£¼·
  • radio-frequency power deposition
    °íÁÖÆÄ µ¿·Â ÃàÀû
  • radio-frequency thermal effect
    °íÁÖÆÄ ¿­ È¿°ú
  • urinary frequency
    ºó´¢
  • vibration frequency
    Áøµ¿ ¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
heat-shock response element <cell biology, protein> The nucleotide sequence, CNNGAANNTCCNG, which is in the promoter region of the heat-shock genes. When the animal is exposed to certain types of stress such as a sudden rise in temperature, the first thing that happens to activate these genes is the binding of the HSE by a transcriptional enhancer protein.
(09 Oct 1997)
Henry-Gauer response Inhibition of antidiuretic hormone secretion due to a rise in atrial pressure which stimulates atrial stretch receptors.
(05 Mar 2000)
satiety response Behavioural response associated with the achieving of gratification.
(12 Dec 1998)
psychogalvanic response A change in electrical resistance of the skin, occurring in emotion and in certain other conditions.
(12 Dec 1998)
secondary antibody response An antibody made upon second (subsequent) exposure to an antigen, mostly of the class IgG.
(09 Oct 1997)
secondary immune response The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen.
(18 Nov 1997)
humoral immune response <immunology> Those immune responses mediated by antibody.
(06 Mar 1998)
serum response element Dyad symmetry element bound by serum response factor to control the expression of c fos.
(18 Nov 1997)
serum response factor Transcription factor that binds to the serum response element upstream of the site of transcription initiation of genes such as c fos.
(18 Nov 1997)
signal response coupling The cascade of processes by which an extracellular signal (typically a hormone or neurotransmitter) interacts with a receptor at the cell surface, causing a change in the level of a second messenger for example calcium or cyclic AMP) and ultimately effects a change in the cells functioning (for example: triggering glucose uptake or initiating cell division). Can also be applied to sensory signal transduction, for example of light at photoreceptors.
(18 Nov 1997)
hypersensitive response An active response of plant cells to pathogenic attack in which the cell undergoes rapid necrosis and dies. Associated with the production of phytoalexins, lignin and sometimes callose. The response is thought to prevent a potential pathogen from spreading through the tissues.
(18 Nov 1997)
sonomotor response Widespread myogenic potential evoked by click stimulation.
(05 Mar 2000)
sos response (genetics) An error-prone mechanism or set of functions for repairing damaged microbial DNA. Sos functions (a concept reputedly derived from the sos of the international distress signal) are involved in DNA repair and mutagenesis, in cell division inhibition, in recovery of normal physiological conditions after DNA repair, and possibly in cell death when DNA damage is extensive.
(12 Dec 1998)
stringent response The cellular response to amino acid starvation that reduces the amount of ribosomes to what can be employed under the nutrient conditions.
(05 Mar 2000)
depletion response Subnormal metabolic response to trauma in a person whose physiologic processes are already depressed by disease.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á